Generic Name: Flavoxate Hydrochloride
Class: Genitourinary Smooth Muscle Relaxants
ATC Class: G04BD02
VA Class: GU201
Chemical Name: 2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate hydrochloride
CAS Number: 3717-88-2
Uses for Urispas
Symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence associated with cystitis, prostatitis, urethritis, urethrocystitis, or urethrotrigonitis. b Not indicated as definitive treatment, but is compatible with drugs used for treatment of urinary tract infections.a
Has not been shown to be more effective in the treatment of these conditions than antimuscarinic agents.a
Urispas Dosage and Administration
Available as flavoxate hydrochloride; dosage expressed in terms of the salt.b
No special population dosage recommendations at this time.b
Cautions for Urispas
Possible increased incidence of mental confusion compared with younger adults.b
Common Adverse Effects
Nausea, vomiting, dry mouth, vertigo, headache, mental confusion, drowsiness, nervousness, blurred vision.b
Interactions for Urispas
Appears to be well absorbed from the GI tract. a
Following oral administration in healthy males, onset of action was 55 minutes.a
Following oral administration in healthy males, peak effect occurred at 112 minutes.a
Not known whether flavoxate is distributed into milk.a
Not known whether flavoxate is dialyzable.a
Increases urinary bladder capacity in patients with evidence of bladder spasticity, possibly as a result of action on the detrusor muscle.a
Advice to Patients
Risk of drowsiness or blurred vision; use caution when driving, operating machinery, or participating in activities where alertness is required.b
Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.b
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.b
Importance of informing patients of other important precautionary information.b (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
AHFS DI Essentials. © Copyright, 2016, American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814. Review Date: September 06, 2016.
a. AHFS drug information 2004. McEvoy GK, ed. Flavoxate. Bethesda, MD: American Society of Health-System Pharmacists; 2007: 3600-1.
b. Ortho-McNeil Pharmaceutical, Inc. Urispas (flavoxate hydrochloride) prescribing and patient information. Raritan, NJ; 2004 Aug.